# Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/synthetic-opioids-schedule-i-placement-butonitazene-flunitazene/ > **Published:** 2026-03-08T19:44:29-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:09:50-04:00 > **Clinical Summary:** Explore the synthetic opioids schedule I placement of butonitazene, flunitazene, and metodesnitazene and their impact on clinical practice and drug policy. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch  |  Regulations.gov PolicySafetyResearch Clinical Summary Clinical Summary The U.S. Drug Enforcement Administration has placed three synthetic opioids—butonitazene, flunitazene, and metodesnitazene—into Schedule I of the Controlled Substances Act, recognizing their high abuse potential and lack of accepted medical use. These novel synthetic opioids have appeared in illicit drug supplies and poison control calls, posing emerging [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) threats similar to fentanyl analogs. While these specific agents are not [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/), this regulatory action reflects the broader landscape of [controlled substance scheduling](https://cedclinic.com/marijuana-rescheduling-regulatory-updates-march-2026/) that parallels cannabis reclassification efforts and affects how clinicians navigate [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/) options and understand evolving drug policies. The placement underscores the DEA’s response to synthetic drug proliferation in unregulated markets, a concern that also applies to illicitly manufactured cannabinoid products. Clinicians should remain vigilant about synthetic opioid contamination in patient drug use histories and recognize that regulatory scheduling changes, whether for opioids or cannabis, reshape the therapeutic landscape available for [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/). The takeaway for practitioners is to stay informed about emerging controlled substances and scheduling changes that may impact [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/) strategies and to counsel patients about risks of illicit products that may contain undisclosed synthetic agents. Clinical Perspective The DEA’s scheduling of three new nitazene opioids (butonitazene, flunitazene, and metodesnitazene) into Schedule I reflects an emerging [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) threat from synthetic opioids that have appeared in illicit drug supplies, often mixed with fentanyl and other potent agents. These compounds, which have potency comparable to fentanyl and morphine, represent a shift in the evolving landscape of novel synthetic opioids that clinicians may encounter in patients presenting with overdose or opioid use disorder. While scheduling provides regulatory control and messaging about abuse potential, it does not directly address the underlying clinical challenge: these substances are already circulating in unregulated supplies, and healthcare providers may have limited ability to detect or manage exposures without reliable field or laboratory testing. The lack of established antidote efficacy data or standardized clinical protocols for nitazene toxidromes adds 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Placement+of+Butonitazene%2C+Flunitazene%2C+and+Metodesnitazene+in+S...+%40drcaplan&url=https%3A%2F%2Fwww.regulations.gov%2Fdocument%2FDEA-2021-0031-0011) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.regulations.gov%2Fdocument%2FDEA-2021-0031-0011) [🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Placement+of+Butonitazene%2C+Flunitazene%2C+and+Metodesnitazene+in+S...+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.regulations.gov%2Fdocument%2FDEA-2021-0031-0011) [📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/) [📝 Read more on Substack](https://substack.com/@doctorapproved) [🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [Regulatory Digest 2026-03-06](https://cedclinic.com/controlled-substances-rescheduling-2026/) - [Regulatory Digest 2026-03-05](https://cedclinic.com/regulatory-cannabis-manufacturing-compliance-2026/) 📰 Source: [https://www.regulations.gov/document/DEA-2021-0031-0011](https://www.regulations.gov/document/DEA-2021-0031-0011) Further Reading CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) Research Digest[Daily Digest 2026-03-07](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) Evidence Watch[`Cannabinoid Clinical Trials: CBD Cortical Excitability Study`](https://cedclinic.com/cannabidiol-lacks-intrinsic-anti-epileptic-properties-trial/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I](https://cedclinic.com/schedules-controlled-substances-placement-schedule-i/) Learn about the DEA's scheduling of additional nitazene opioids and their implications for public health and clinical practice. [Read More](https://cedclinic.com/schedules-controlled-substances-placement-schedule-i/) [Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I](https://cedclinic.com/synthetic-ketamine-analog-regulation-temporary-scheduling/) Review the temporary scheduling of 2-Fluorodeschloroketamine and its relevance to emerging synthetic drug threats. [Explore Details](https://cedclinic.com/synthetic-ketamine-analog-regulation-temporary-scheduling/) [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) Understand the regulatory actions surrounding synthetic cannabinoids like CUMYL-PEGACLONE and their scheduling status. [Learn More](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).